ER2 Frailty Levels and Incident Adverse Health Events in Older Community Dwellers

Association Between Emergency Room Evaluation and Recommendations Tool (ER2) Frailty Levels and Incident Adverse Health Events in Older Community Dwellers: Results of the NuAge Study

Older adults' health and functional status are heterogeneous because of the various cumulative effects of chronic diseases and physiologic decline, contributing to a vicious cycle of increased frailty 1-4. Thanks to advances in medicine and hygiene, a growing number of older adults spend more years with a greater range of chronic diseases causing disability but not mortality 5. Health systems need to face this new challenge 4,5. Quantification of frailty and its association with the occurrence of incident adverse health events (i.e., functional decline, unplanned hospitalizations) is crucial to understand how health systems may efficiently respond to this situation 6. This study aims to examine the association of the ER2 tool score and its stratification in three levels for incident adverse health events in older community dwellers and to compare this association with three validity frailty indexes which are the Cardiovascular Health Study (CHS) frailty index, Study of Osteoporotic Fracture (SOF) index and Rockwood frailty index.

Study Overview

• Status: Unknown
• Conditions: Emergencies; Frailty; Aging
• Intervention / Treatment: Other: No intervention: secondary use of a database

• Study Type: Observational
• Enrollment (Anticipated): 1741

Contacts and Locations

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Child; Adult; Older Adult
• Accepts Healthy Volunteers: Yes
• Genders Eligible for Study: All

• Sampling Method: Non-Probability Sample

Study Population

Individuals eligible for this study will be participants of the NuAge study who agreed to be part of the NuAge Database and Biobank for future research purposes

Description

Inclusion Criteria:

• All enrolled participants of NuAge Study who agreed to be part of the NuAge Database and Biobank for future research purposes

Exclusion Criteria:

• Missing data
• Participants' refusal to use their data for a purpose not identified during their recruitment.

Study Plan

How is the study designed?

Number of groups / cohorts

1

Cohorts and Interventions

Group / Cohort	Intervention / Treatment
NuAge participants; All Individuals of the NuAge study who agreed to be part of the NuAge Database for future research purposes	Other: No intervention: secondary use of a database; Statistical analyses

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
ER2	6-item questionnaire determining a stratification of frailty risk in three levels (Low, moderate, high)	4 years
SOF index	index with 3 items determining a level of frailty from 0 (patient is vigorous) to 1 (patient is pre-frail)	4 years
CHS index	index with 5 items determining a level of frailty from 0 component positive (patient is vigorous), 1 or 2 positive components (patient is in an intermediate stage) to 3 or more positive components (patients is frail)	4 years
Rockwood index	index determining a level of frailty from 0 to 17 (less than 5: patient is vigorous, between 6 and 11 patient is apparently vulnerable and above 12 patient is in severe frailty)	4 years
Physical functional decline	annual variation of physical functional score available in the Nuage database	4 years
Falls	presence or absence of falls, information available in the Nuage database	4 years
Hospitalizations	presence or absence of hospitalizations, information available in the Nuage database	4 years
Mortality	death of the participant, information available in the Nuage database	4 years

Collaborators and Investigators

• Sponsor: Jewish General Hospital
• Investigators: Principal Investigator: Cyrille Launay, MD, Jewish General Hospital

Study record dates

Study Major Dates

• Study Start (Anticipated): September 1, 2020
• Primary Completion (Anticipated): September 1, 2021
• Study Completion (Anticipated): September 1, 2021

Study Registration Dates

• First Submitted: June 11, 2020
• First Submitted That Met QC Criteria: June 11, 2020
• First Posted (Actual): June 16, 2020

Study Record Updates

• Last Update Posted (Actual): June 16, 2020
• Last Update Submitted That Met QC Criteria: June 11, 2020
• Last Verified: June 1, 2020

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Pathologic Processes; Disease Attributes; Emergencies; Frailty
• Other Study ID Numbers: 2021-2432

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO
• IPD Plan Description: The databank property is not ours. We do not have the right to share IPD.

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No